We advised the underwriters on the concurrent offerings

Davis Polk advised the representatives of the several underwriters in connection with a $1.725 billion SEC-registered offering of 12,147,887 shares of common stock by Revolution Medicines, Inc. and an SEC-registered offering of an aggregate principal amount of $500 million of its 0.50% convertible senior notes due 2033. The proceeds from the offerings will be used for general corporate purposes.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.

The Davis Polk capital markets team included partners Alan F. Denenberg and Yasin Keshvargar and associates Paula Gergen, Brendon S. Brown, Hannah R. Carter and Naomi Zhao. Partner Lucy W. Farr, counsel Yixuan Long and associate Valentin Van de Walle provided tax advice. Partner David R. Bauer provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post